Psyence Biomed, a division of Psyence specializing in natural psilocybin products, has decided not to proceed with acquiring Clairvoyant Therapeutics, which was announced in September 2024 , following the completion of due diligence and pre-closing activities.
Psyence Biomed will continue to focus on its development programs, including a Phase IIb clinical trial for adjustment disorder in palliative care and a program for substance use disorders, particularly alcohol use disorder. The company also plans to provide updates on its pending acquisition of an 11.13% stake in PsyLabs, also announced in September 2024 .
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.